Robert Stoltz, MD
Ophthalmology · Marietta, GANPI 1275584047
Payments from drug & device makers
What this record shows
The money is spread across several categories — ownership interests (53.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by US Retina LLC at 53.2% of the total. Reporting peaked in 2022 at $18,124 and has fallen 96.5% since, to $642 in 2025. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $263.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$29K
- Genentech USA, Inc.$17K
- Regeneron$2K
- Genentech, Inc.$1K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $3K from 14 others
Across 443 payments — averaging $8692.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3M
- Apellis Pharmaceuticals, Inc.$294K
- Novartis$223K
- Regeneron$221K
- Janssen Research & Development, LLC$67K
- AbbVie$33K
- plus $36K from 3 others
What the payments were for
- Consulting fees$14,86827%
- Travel & lodging$3,0156%
- Food & beverage$7,55614%
- Ownership interest$28,86853%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $28,868 |
| Genentech USA, Inc. | 40 | $16,764 |
| Regeneron | 1 | $1,848 |
| Genentech, Inc. | 9 | $1,324 |
| AbbVie(2 entities) | 36 | $1,110 |
| Regeneron Healthcare Solutions, Inc. | 31 | $1,022 |
| Alcon | 8 | $562 |
| Apellis Pharmaceuticals, Inc. | 11 | $473 |
| Novartis | 14 | $403 |
| Carl Zeiss Meditec USA, Inc. | 4 | $396 |
| Bausch & Lomb Americas Inc. | 3 | $311 |
| ANI Pharmaceuticals, Inc. | 5 | $310 |
| Astellas Pharma US Inc | 9 | $243 |
| Coherus Oncology, Inc. | 10 | $211 |
| Eyepoint US, Inc. | 4 | $180 |
| Alimera Sciences, Inc. | 9 | $158 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Sandoz | 1 | $34 |
| Mallinckrodt Enterprises LLC | 2 | $30 |
| Biogen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$16,031
- EYLEA HD$1,958
- Non-Covered Product$976
- OZURDEX$426
- XIPERE$288
- Constellation$286
- Syfovre$265
- EYLEA$234
- Iluvien$216
- NGENUITY$150
- VISUDYNE$145
- Lucentis$141
- Clarus 700$133
- CLARUS$128
- YUTIQ$128
- CIRRUS HD-OCT$120
How this compares
$54,306 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 101 | $4,116 |
| Atropine Sulfate | 46 | $1,330 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 50 | $758 |
| Latanoprost | 53 | $529 |
| Brimonidine Tartrate | 17 | $333 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 46 | $315 |
| Ciprofloxacin Hcl | 24 | $311 |
| Timolol Maleate | 29 | $272 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 24 | $229 |
| Ketorolac Tromethamine | 15 | $138 |
| Diclofenac Sodium | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Marietta
- Puneet PandaMarietta$185K
- Annal MelethMarietta$34K
- Hersh ChopraMarietta$16K
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Jeffrey TranSuwanee$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.